首页> 外文OA文献 >Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

【2h】

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

机译：Brentuximab-vEdotin与地塞米松，高剂量含有高剂量酸碱和顺铂相结合的I相剂量 - 升级研究，作为复发/难治性典型霍奇金淋巴瘤的救生处理：Hovon / LLPC移植勇敢的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Anton Hagenbeek; Hans Mooij; Josée Zijlstra; Pieternella Lugtenburg; Gustaaf van Imhoff; Marcel Nijland; Sanne Tonino; Martin Hutchings; Marjolein Spiering; Roberto Liu; Harm van Tinteren; Marie José Kersten;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. 高剂量化放疗联合自体造血干细胞移植治疗霍奇金淋巴瘤11例报告 [J] . 周生余, 石远凯, 何小慧, 癌症（英文版） . 2002,第004期
2. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study [J] . Marie José Kersten, Julia Driessen, Josée M. Zijlstra, Haematologica . 2021,第4期

机译：将Brentuximab Vedotin与地塞米松，高剂量的细胞甘油和顺铂作为复发或难治性Hodgkin淋巴瘤的打捞治疗：II期Hovon / LLPC移植勇敢的研究
3. Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.” [J] . Marco Picardi, Claudia Giordano Haematologica . 2021,第4期

机译：评论“将布伦克西非塞酮与地塞塞酮，高剂量的糖蛋白和顺铂结合在复发霍奇金淋巴瘤中的打捞治疗：II阶层HOVON / LLPC移植勇敢的研究。”
4. Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study [J] . Hagenbeek Anton, Zijlstra Josee M., Plattel Wouter J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：将Brentuximab Vedotin与DHAP结合为复发/难治性Hodgkin淋巴瘤的救生处理：II期HOVON / LLPC移植勇敢的研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone high-dose cytarabine and cisplatin as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study [O] . Anton Hagenbeek, Hans Mooij, Josée Zijlstra, 2019

机译：brentuximab-vedotin联合地塞米松大剂量阿糖胞苷和顺铂作为挽救治疗复发/难治性经典霍奇金淋巴瘤的一期剂量递增研究：HOVON / LLPC移植物BRaVE研究
7. LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY [O] . J. Driessen, M. J. Kersten, L. Visser, 2021

机译：在复发/难治性Hodgkin淋巴瘤患者中布伦克西巴布vedotin和Dhap的长期随访和生物标志物分析：Hovon / LLPC移植勇敢的研究

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

著录项

相似文献

相关主题

期刊订阅